Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00154102




Registration number
NCT00154102
Ethics application status
Date submitted
8/09/2005
Date registered
12/09/2005
Date last updated
30/01/2017

Titles & IDs
Public title
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
Scientific title
Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer
Secondary ID [1] 0 0
EMR 62202-013
Universal Trial Number (UTN)
Trial acronym
CRYSTAL
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cetuximab
Treatment: Drugs - FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Experimental: Cetuximab Plus FOLFIRI -

Active comparator: FOLFIRI Alone -


Treatment: Drugs: Cetuximab
Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops

Treatment: Drugs: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
Timepoint [1] 0 0
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Primary outcome [2] 0 0
Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments
Timepoint [2] 0 0
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Primary outcome [3] 0 0
Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
Timepoint [3] 0 0
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Secondary outcome [1] 0 0
Overall Survival Time (OS)
Timepoint [1] 0 0
Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Secondary outcome [2] 0 0
Overall Survival Time (KRAS Wild-Type Population)
Timepoint [2] 0 0
Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Secondary outcome [3] 0 0
Overall Survival Time (KRAS Mutant Population)
Timepoint [3] 0 0
Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Secondary outcome [4] 0 0
Best Overall Response Rate - Independent Review Committee (IRC) Assessments
Timepoint [4] 0 0
evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Secondary outcome [5] 0 0
Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments
Timepoint [5] 0 0
evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Secondary outcome [6] 0 0
Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
Timepoint [6] 0 0
evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Secondary outcome [7] 0 0
Disease Control Rate - Independent Review Committee (IRC) Assessments
Timepoint [7] 0 0
Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Secondary outcome [8] 0 0
Duration of Response - Independent Review Committee (IRC) Assessments
Timepoint [8] 0 0
Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Secondary outcome [9] 0 0
Participants With No Residual Tumor After Metastatic Surgery
Timepoint [9] 0 0
time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
Secondary outcome [10] 0 0
Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
Timepoint [10] 0 0
at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Secondary outcome [11] 0 0
Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
Timepoint [11] 0 0
at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Secondary outcome [12] 0 0
Safety - Number of Patients Experiencing Any Adverse Event
Timepoint [12] 0 0
time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007

Eligibility
Key inclusion criteria
* Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum
* Inoperable metastatic disease
* Immunohistochemical evidence of epidermal growth factor receptor expression in tumor tissue
* Presence of at least 1 bi-dimensionally measurable index lesion
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Previous irinotecan-based chemotherapy
* Previous chemotherapy for colorectal cancer except adjuvant treatment if terminated more than 6 months before the start of study treatment
* Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of study treatment
* Brain metastasis

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2004
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2011
Sample size
Target
Accrual to date
Final
1221
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Bedford Park
Recruitment hospital [2] 0 0
Research Site - Darlinghurst
Recruitment hospital [3] 0 0
Research Site - Heidelberg
Recruitment hospital [4] 0 0
Research Site - Nedlands
Recruitment hospital [5] 0 0
Research Site - West Perth
Recruitment hospital [6] 0 0
Research Site - Woodville
Recruitment postcode(s) [1] 0 0
- Bedford Park
Recruitment postcode(s) [2] 0 0
- Darlinghurst
Recruitment postcode(s) [3] 0 0
- Heidelberg
Recruitment postcode(s) [4] 0 0
- Nedlands
Recruitment postcode(s) [5] 0 0
- West Perth
Recruitment postcode(s) [6] 0 0
- Woodville
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Austria
State/province [2] 0 0
Innsbruck
Country [3] 0 0
Austria
State/province [3] 0 0
Klagenfurt
Country [4] 0 0
Austria
State/province [4] 0 0
Kufstein
Country [5] 0 0
Austria
State/province [5] 0 0
Salzburg
Country [6] 0 0
Austria
State/province [6] 0 0
St. Pölten
Country [7] 0 0
Austria
State/province [7] 0 0
St. Veit an der Glan
Country [8] 0 0
Austria
State/province [8] 0 0
Wels
Country [9] 0 0
Austria
State/province [9] 0 0
Wien
Country [10] 0 0
Belgium
State/province [10] 0 0
Antwerpen
Country [11] 0 0
Belgium
State/province [11] 0 0
Bonheiden
Country [12] 0 0
Belgium
State/province [12] 0 0
Bruxelles
Country [13] 0 0
Belgium
State/province [13] 0 0
Edegem
Country [14] 0 0
Belgium
State/province [14] 0 0
Gent
Country [15] 0 0
Belgium
State/province [15] 0 0
Leuven
Country [16] 0 0
Belgium
State/province [16] 0 0
Liège
Country [17] 0 0
Brazil
State/province [17] 0 0
Goiania
Country [18] 0 0
Brazil
State/province [18] 0 0
Porto Alegre
Country [19] 0 0
Brazil
State/province [19] 0 0
Santo André
Country [20] 0 0
Brazil
State/province [20] 0 0
Sao Paulo
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Pleven
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Plovidiv
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sofia
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Varna
Country [25] 0 0
Chile
State/province [25] 0 0
Santiago-Las Condes
Country [26] 0 0
Chile
State/province [26] 0 0
Santiago-Providencia
Country [27] 0 0
Czech Republic
State/province [27] 0 0
Chomutov
Country [28] 0 0
Czech Republic
State/province [28] 0 0
Prague
Country [29] 0 0
Finland
State/province [29] 0 0
Turku
Country [30] 0 0
France
State/province [30] 0 0
Bordeaux
Country [31] 0 0
France
State/province [31] 0 0
Boulogne-Billancourt
Country [32] 0 0
France
State/province [32] 0 0
Colmar
Country [33] 0 0
France
State/province [33] 0 0
Grenoble
Country [34] 0 0
France
State/province [34] 0 0
La Roche sur Yon
Country [35] 0 0
France
State/province [35] 0 0
Lorient
Country [36] 0 0
France
State/province [36] 0 0
Marseille
Country [37] 0 0
France
State/province [37] 0 0
Nantes
Country [38] 0 0
France
State/province [38] 0 0
Perigueux
Country [39] 0 0
France
State/province [39] 0 0
Rennes Cedex
Country [40] 0 0
France
State/province [40] 0 0
Saint Gregoire
Country [41] 0 0
France
State/province [41] 0 0
Strasbourg
Country [42] 0 0
France
State/province [42] 0 0
Toulon
Country [43] 0 0
France
State/province [43] 0 0
Villejuif Cedex
Country [44] 0 0
Germany
State/province [44] 0 0
Dortmund
Country [45] 0 0
Germany
State/province [45] 0 0
Dresden
Country [46] 0 0
Germany
State/province [46] 0 0
Düsseldorf
Country [47] 0 0
Germany
State/province [47] 0 0
Essen
Country [48] 0 0
Germany
State/province [48] 0 0
Frankfurt am Main
Country [49] 0 0
Germany
State/province [49] 0 0
Freiburg
Country [50] 0 0
Germany
State/province [50] 0 0
Göttingen
Country [51] 0 0
Germany
State/province [51] 0 0
Halle
Country [52] 0 0
Germany
State/province [52] 0 0
Hamburg
Country [53] 0 0
Germany
State/province [53] 0 0
Heidelberg
Country [54] 0 0
Germany
State/province [54] 0 0
Homburg/Saar
Country [55] 0 0
Germany
State/province [55] 0 0
Jena
Country [56] 0 0
Germany
State/province [56] 0 0
Mainz
Country [57] 0 0
Germany
State/province [57] 0 0
Mannheim
Country [58] 0 0
Germany
State/province [58] 0 0
München
Country [59] 0 0
Germany
State/province [59] 0 0
Oldenburg
Country [60] 0 0
Germany
State/province [60] 0 0
Ulm
Country [61] 0 0
Greece
State/province [61] 0 0
Alexandroupolis
Country [62] 0 0
Greece
State/province [62] 0 0
Athens
Country [63] 0 0
Greece
State/province [63] 0 0
Heraklion
Country [64] 0 0
Hong Kong
State/province [64] 0 0
Pokfulam
Country [65] 0 0
Hong Kong
State/province [65] 0 0
Shatin
Country [66] 0 0
Hungary
State/province [66] 0 0
Budapest
Country [67] 0 0
Hungary
State/province [67] 0 0
Debrecen
Country [68] 0 0
Hungary
State/province [68] 0 0
Györ
Country [69] 0 0
Hungary
State/province [69] 0 0
Kecskemét
Country [70] 0 0
Hungary
State/province [70] 0 0
Pécs
Country [71] 0 0
Italy
State/province [71] 0 0
Ancona
Country [72] 0 0
Italy
State/province [72] 0 0
Aviano
Country [73] 0 0
Italy
State/province [73] 0 0
Bari
Country [74] 0 0
Italy
State/province [74] 0 0
Benevento
Country [75] 0 0
Italy
State/province [75] 0 0
Firenze
Country [76] 0 0
Italy
State/province [76] 0 0
Mantova
Country [77] 0 0
Italy
State/province [77] 0 0
Milano
Country [78] 0 0
Italy
State/province [78] 0 0
Modena
Country [79] 0 0
Italy
State/province [79] 0 0
Napoli
Country [80] 0 0
Italy
State/province [80] 0 0
Reggio Emilia
Country [81] 0 0
Italy
State/province [81] 0 0
Roma
Country [82] 0 0
Italy
State/province [82] 0 0
Rozzano
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Seoul
Country [84] 0 0
Mexico
State/province [84] 0 0
Mexico
Country [85] 0 0
Netherlands
State/province [85] 0 0
Amsterdam
Country [86] 0 0
Netherlands
State/province [86] 0 0
Apeldoom
Country [87] 0 0
Netherlands
State/province [87] 0 0
Blaricum
Country [88] 0 0
Netherlands
State/province [88] 0 0
Den Haag
Country [89] 0 0
Netherlands
State/province [89] 0 0
Roosendaal
Country [90] 0 0
Netherlands
State/province [90] 0 0
Zwolle
Country [91] 0 0
Poland
State/province [91] 0 0
Bialystok
Country [92] 0 0
Poland
State/province [92] 0 0
Gliwice
Country [93] 0 0
Poland
State/province [93] 0 0
Krakow
Country [94] 0 0
Poland
State/province [94] 0 0
Opole
Country [95] 0 0
Poland
State/province [95] 0 0
Poznan
Country [96] 0 0
Poland
State/province [96] 0 0
Warsaw
Country [97] 0 0
Poland
State/province [97] 0 0
Wroclaw
Country [98] 0 0
Romania
State/province [98] 0 0
Cluj Napoca
Country [99] 0 0
Romania
State/province [99] 0 0
Iasi
Country [100] 0 0
Romania
State/province [100] 0 0
Suceava
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Moscow
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Saint Petersburg
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Yaroslavl
Country [104] 0 0
Singapore
State/province [104] 0 0
Singapore
Country [105] 0 0
Slovakia
State/province [105] 0 0
Banska Bystrica
Country [106] 0 0
Slovakia
State/province [106] 0 0
Bratislava
Country [107] 0 0
Slovakia
State/province [107] 0 0
Kosice
Country [108] 0 0
Slovakia
State/province [108] 0 0
Trnava
Country [109] 0 0
Slovakia
State/province [109] 0 0
Zilina
Country [110] 0 0
South Africa
State/province [110] 0 0
Cape Town
Country [111] 0 0
South Africa
State/province [111] 0 0
Durban
Country [112] 0 0
South Africa
State/province [112] 0 0
Johannesburg
Country [113] 0 0
South Africa
State/province [113] 0 0
Port Elizabeth
Country [114] 0 0
South Africa
State/province [114] 0 0
Pretoria
Country [115] 0 0
Spain
State/province [115] 0 0
A Coruna
Country [116] 0 0
Spain
State/province [116] 0 0
Barcelona
Country [117] 0 0
Spain
State/province [117] 0 0
Cadiz
Country [118] 0 0
Spain
State/province [118] 0 0
Madrid
Country [119] 0 0
Spain
State/province [119] 0 0
Palma de Mallorca
Country [120] 0 0
Spain
State/province [120] 0 0
Valencia
Country [121] 0 0
Sweden
State/province [121] 0 0
Göteborg
Country [122] 0 0
Sweden
State/province [122] 0 0
Stockholm
Country [123] 0 0
Taiwan
State/province [123] 0 0
Changhua
Country [124] 0 0
Taiwan
State/province [124] 0 0
Chiayi
Country [125] 0 0
Taiwan
State/province [125] 0 0
Taipei
Country [126] 0 0
Taiwan
State/province [126] 0 0
Taoyuan
Country [127] 0 0
Turkey
State/province [127] 0 0
Ankara
Country [128] 0 0
Turkey
State/province [128] 0 0
Istanbul
Country [129] 0 0
Turkey
State/province [129] 0 0
Izmir
Country [130] 0 0
Ukraine
State/province [130] 0 0
Charkassy
Country [131] 0 0
Ukraine
State/province [131] 0 0
Donetsk
Country [132] 0 0
Ukraine
State/province [132] 0 0
Ivano-Frankivsk
Country [133] 0 0
Ukraine
State/province [133] 0 0
Kiev
Country [134] 0 0
Ukraine
State/province [134] 0 0
Krivoy Rog
Country [135] 0 0
Ukraine
State/province [135] 0 0
Lugansk
Country [136] 0 0
Ukraine
State/province [136] 0 0
Lviv
Country [137] 0 0
Ukraine
State/province [137] 0 0
Uzhgorod
Country [138] 0 0
Ukraine
State/province [138] 0 0
Zhaporozhye
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Brighton
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Cambridge
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Glasgow
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Guildford
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Kent
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Leicester
Country [145] 0 0
United Kingdom
State/province [145] 0 0
London
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Peterborough
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Rhyl
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck KGaA, Darmstadt, Germany
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Giving combination chemotherapy together with cetuximab as first treatment after diagnosis of a metastatic colorectal cancer ('1st-line' treatment) may improve the treatment efficacy. However, it is not yet known whether giving combination chemotherapy together with cetuximab is more effective than combination chemotherapy alone. This open-label trial investigates the effectiveness of cetuximab in combination with a standard and effective chemotherapy (5-Fluorouracil (5FU)/Folinic acid (FA) plus irinotecan) for metastatic colorectal cancer in first-line setting, compared to the same chemotherapy alone on patient expressing the epidermal growth factor (EGF) receptor.

Patients expressing this EGF Receptor will be randomly assign in one of the 2 groups to either receive the combination chemotherapy alone or with cetuximab (open-label study) and will then be treated until progression of the disease or unacceptable toxicity occur. Regular efficacy assessments (every 8 weeks) based on imaging will be performed throughout the study together with regular safety assessments (e.g. safety labs). An independent Safety Board of experts will also monitor safety data.

After participant discontinuation from the trial, regular updates on further treatments and survival status will be requested from the investigator.

The entire study (from the first patient entering the study to the last collect of follow-up information) is 4-5 years long.
Trial website
https://clinicaltrials.gov/study/NCT00154102
Trial related presentations / publications
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.
Van Cutsem E, Lang I, Folprecht G, Nowacki M, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Celik I, Kohne C Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, USA January 2010 Abstract No: 281
Lang I, Kohne CH, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Zubel A, Van Cutsem E Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial. European Journal of Cancer Supplements. 2009 7(2):345
Dercle L, Lu L, Lichtenstein P, Yang H, Wang D, Zhu J, Wu F, Piessevaux H, Schwartz LH, Zhao B. Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. JCO Clin Cancer Inform. 2017 Nov;1:1-8. doi: 10.1200/CCI.17.00108.
Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017 Feb 1;3(2):194-201. doi: 10.1001/jamaoncol.2016.3797. Erratum In: JAMA Oncol. 2017 Dec 1;3(12):1742. doi: 10.1001/jamaoncol.2017.4136.
Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19.
Public notes

Contacts
Principal investigator
Name 0 0
Eric van Cutsem, Professor
Address 0 0
University Hospital Gasthuisberg, Department Internal Medicine, Leuven, Belgium
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00154102